Your browser doesn't support javascript.
loading
Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.
Landau, H; Smith, M; Landry, C; Chou, J F; Devlin, S M; Hassoun, H; Bello, C; Giralt, S; Comenzo, R L.
Afiliação
  • Landau H; Department of Medicine, New York-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA.
  • Smith M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Landry C; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chou JF; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Devlin SM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Hassoun H; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Bello C; Department of Medicine, New York-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA.
  • Giralt S; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Comenzo RL; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Leukemia ; 31(1): 136-142, 2017 01.
Article em En | MEDLINE | ID: mdl-27560108
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Amiloidose / Melfalan Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Amiloidose / Melfalan Idioma: En Ano de publicação: 2017 Tipo de documento: Article